Ongoing phase I/II clinical trials investigating the safety and efficacy of i.t. injection of AAV9-ABCD1 for adrenomyeloneuropathy in adult patients since 2022 (NCT05394064) represent a significant step toward elucidating the therapeutic potential of AAV-based gene therapy in ALD. Here, ABCD1 is linked to X-linked adrenoleukodystrophy.